Is gosatuzumab (Todavi) a targeted drug or an immunotherapy drug?

Gosatuzumab (English name: Sacituzumab Govitecan, trade name: Trodelvy) is an antibody drug conjugate (ADC). Its therapeutic mechanism is neither completely equivalent to traditional targeted drugs nor immune checkpoint inhibitors, but its essence is a specific form of targeted drugs. ADCThe core feature of the drug is that it combines the dual advantages of targeted antibodies and cytotoxic chemotherapy drugs to kill cancer cells by accurately locating tumor cells and releasing toxic components.

Trodelvy consists of three parts: First, the targeting antibody sacituzumab, which can accurately identify on the surface of cancer cells Trop-2protein; the second is a linker, connecting the antibody to the toxin; the third is a powerful chemotherapeutic toxinSN-38 (the active metabolite of irinotecan). This design enables Trodelvy to selectively enter Trop-2 cancer cells with high expression, such as triple-negative breast cancer ( pan>TNBC) or urothelial cancer, after entering the cells, it releases SN-38 for local killing, thus greatly reducing the toxic effects on normal cells.

AlthoughTrodelvy has the ability to "target" recognize cancer cells, it does not activate the body's immune system to fight tumors and does not fall into the category of PD-1/PD-L1 inhibitors or CAR-T cell therapy among immunotherapy drugs. Its mechanism is closer to the advanced model of "precision delivery chemotherapy", so it is usually classified as an "ADCtargeted drug".

In short, gosatuzumab (Trodelvy) is an advanced targeted therapy drug that belongs to the category of antibody drug conjugates (ADC). It delivers cytotoxic drugs by targeting Trop-2 protein, which not only improves treatment accuracy but also reduces side effects. It is currently one of the important treatment options for triple-negative breast cancer and urothelial cancer, but it does not fall into the category of traditional immunotherapy.

Reference: https://go.drugbank.com/drugs/